Generic Name and Formulations:
Chloroprocaine HCl 10mg/mL, 20mg/mL; soln for inj; contains methylparaben.
Fresenius Kabi USA
Indications for NESACAINE:
Production of local anesthesia by infiltration and peripheral nerve block.
Epidural anesthesia: administer test dose first; monitor for CNS or cardiovascular toxicity. See full labeling for dosing based on procedure. Individualize. Max single recommended dose: 11mg/kg, not to exceed max total dose of 800mg. Debilitated, elderly, acutely ill (cardiac and/or liver disease): reduce dose.
<3yrs: see full labeling. Individualize based on age and weight. ≥3yrs: max 11mg/kg.
Not for subarachnoid administration. Lumbar and caudal epidural anesthesia: caution with existing neurological disease, spinal deformities, septicemia, severe hypertension. To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Hypotension. Heart block. Monitor cardiovascular and respiratory vital signs. Impaired cardiovascular function. Hepatic impairment. Retrobulbar block. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Concomitant sulfonamides: not recommended. Concurrent vasopressor and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others.
CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tremors), cardiovascular effects (eg, myocardium depression, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, spinal block, urinary retention, paresthesia, weakness, headache, paralysis of lower extremities).
Nesacaine: Multi-dose vial (30mL)—25; Nesacaine-MPF: Single-dose vial (20mL)—25
Renal and Urology News Articles
- Kidney Damage in Younger Adults Tied to NSAID Use
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Guidelines Updated for Pulmonary Arterial Hypertension in Adults
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Darolutamide Improves Metastasis-Free Survival in CRPC
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)